Details for Patent: 9,221,788

« Back to Dashboard

Which drugs does patent 9,221,788 protect, and when does it expire?

Patent 9,221,788 protects ZENBEXUS and is included in one NDA.

This patent has fifty patent family members in thirty-six countries.

Summary for Patent: 9,221,788

Title:	Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
Abstract:	Salts and solid forms of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a stereoisomer thereof, are disclosed. Compositions comprising and methods of using the salts and solid forms are also disclosed.
Inventor(s):	Benjamin M. Cohen, John F. Traverse, Jean Xu, Ying Li
Assignee:	Celgene Corp
Application Number:	US13/962,745
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,221,788

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-001	Aug 13, 2026		RX	Yes	No	9,221,788			Y
Bristol Myers Squibb	ZENBEXUS	iberdomide hydrochloride	CAPSULE;ORAL	221075-002	Aug 13, 2026		RX	Yes	Yes	9,221,788			Y

International Family Members for US Patent 9,221,788

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	094997
Australia	2013299631
Brazil	112015001874